Pneumrx, Inc.

Baxter International Inc.

Matrix Medical LLC

Tenaxis Medical, Inc.

Medtronic, Inc.

Mallinckrodt Pharma IP Trading D.a.c.

Micro Interventional Systems, Inc.

Ronald Dieck

Glen Gong

Erin McGurk

Kemal Schankereli

Ian J Handley

Neil Winterbottom

Joanna Wong

Mark L Mathis

Patrick Peichen Wu

David Lehrberg

Jaime Vasquez

Andrew Stein

William Stephen Tremulis

Charles Wartchow

Erin Mcgurk

Jobert P Balceta

Joanna Wang

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. The subject phase invertible compositions are prepared by combining a proteinaceous substrate and a crosslinking agent, such as a stabilized aldehyde crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.

Biocompatible phase invertable proteinaceous compositions and methods for making and using the same

The present invention relates to methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume. The glue compositions provide a glue featuring an adhering moiety coupled to one or more other moieties including, for example, a cross-linkable moiety and/or one other adhering moiety. The methods and compositions of the invention find use, for example, in treating pulmonary conditions, such as emphysema.

Glue composition for lung volume reduction

Elongate implant structures can be introduced into an airway system to a target airway axial region, often to apply lateral bending and/or compression forces against the lung tissue from within the airways for an extended period of time. Structures or features of the implants may inhibit tissue reactions that might otherwise allow portions of the device to eventually traverse through the wall of the airway. The devices may enhance the area bearing laterally on the tissue of a surrounding airway lumen wall. Embodiments may have features which increase the device friction with the airway to allow the device to grip the surrounding airway as the device is deployed. An appropriate adhesive may be introduced around the device in the lung. Hydrophilic material may inhibit biofilm formation, or features which induce some tissue ingrowth (stimulation of tissue growth) may enhance implanted device supported.

Cross-sectional modification during deployment of an elongate lung volume reduction device

Growing community of inventors

Palo Alto, CA, United States of America

Ronald Dieck